Coronavirus collaterals

COVID-19 could cause 20% rise in cancer deaths

The COVID-19 pandemic could, over the next year, lead to a 20% rise in the number of deaths from people who have been newly diagnosed with cancer, according to research supported by DATA-CAN

The analysis is the first to focus on the impact of the emergency on mortality rates in people with cancer and uses data from the health records of over 3.5 million patients in England. The University of Leeds and Leeds Teaching Hospitals are founding partners of DATA-CAN, a multi-million pound initiative that collects health data across the UK, led by University College London.

Photo
Cancer cells in culture from human connective tissue, illuminated by darkfield amplified contrast, at a magnification of 500x

Image source: Dr. Cecil Fox (Photographer), Cancer cells (1), marked as public domain, details at Wikimedia Commons

The study estimates that pre-COVID-19, about 31,354 newly diagnosed cancer patients would die within a year in England. As a result of the emergency, there could be at least 6,270 additional deaths in newly diagnosed cancer patients alone. This number could rise to an estimated 17,915 additional deaths if all people currently living with cancer are considered. The researchers analysed recent weekly data from major cancer centres in the UK and found a 76% decrease in urgent referrals from GPs for people with suspected cancers and a 60% decrease in chemotherapy appointments for cancer patients compared to pre-COVID-19 levels. 

Professor Geoff Hall is a Professor of Digital Health and Cancer Medicine at the University of Leeds and an Honorary Consultant in Medical Oncology at Leeds Teaching Hospitals NHS Trust. He is a co-author of the report, and clinical lead of DATA-CAN. He said: “We are concerned about the dramatic drop in referrals from GPs to cancer services which the data only too clearly demonstrates. This is the similar to the drop we see at Christmas, but the effect has been sustained since early February.”

Recommended article

Photo

Coronavirus impact on A&E

COVID-19: UK emergency departments see dramatic fall in attendance

Accident and Emergency departments across the NHS have seen dramatic falls in attendances amid the ongoing coronavirus crisis. Latest figures for NHS England show that the total number of attendances at A&E departments in March 2020 was 1,531,100, a decrease of 29.4% on the same month last year. And while the figures are specifically for England, a similar pattern has been observed across the…

Monica Jones, Chief Data Officer of DATA-CAN and Exec Lead for Population Health Management for the digitised Yorkshire and Humber Care Record, which is supported by the Yorkshire and Humber AHSN, added: “It’s crucial that we can now use the anonymised data from the Integrated Care Record to serve the entire region of Yorkshire and Humber with real-time information. We have used information from the Leeds area, now we can work region-wide with a population of over 5 million. This will inform us how health services should be prioritised, both now and in the near future, in order to give patients the best possible life chances.”

Collaborators from Yorkshire and Humber also include the University of Leeds, Leeds Teaching Hospitals NHS Trust, University of Sheffield, Sheffield Teaching Hospitals, Sheffield Children’s Hospital, the Yorkshire and Humber Local Health Care Record, and Yorkshire & Humber AHSN.

The overall impact of the COVID-19 emergency on deaths in cancer patients could be substantial

Harry Hemingway

Dr Neville Young, Yorkshire & Humber AHSN’s Director of Enterprise and Innovation, said: “This is an important piece of research that will affect how the healthcare systems thinks about cancer patients during COVID-19 pandemic. It was only possible because of both the data within and the collaborative approach of the DATA-CAN partners. This is another great digital health asset for the Yorkshire and Humber region that sits alongside the Yorkshire and Humber Care Record and the Northern Pathology Imaging Cooperative that is starting to prove its worth.”

Senior author Professor Harry Hemingway, (Director, UCL Institute of Health Informatics), added: “The overall impact of the COVID-19 emergency on deaths in cancer patients could be substantial. There are many factors operating here including rapid changes to diagnosis and treatment protocols, social distancing measures, changes in people’s behaviour in seeking medical attention and the economic impact of COVID-19, as well as deaths due to COVID-19 infection.”

The DATA-CAN paper also models publicly available US data and shows an additional 33,890 deaths in the US in newly diagnosed cancer patients over the next year. The study estimates that pre-COVID-19, about 169,433 newly diagnosed cancer patients would die within a year in the US.


Source: University of Leeds

30.04.2020

Read all latest stories

Related articles

Photo

BTK inhibitor vs. respiratory distress

Off-label cancer drug shows promise against severe COVID-19

Early data from a clinical study suggest that blocking the Bruton tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19. Researchers observed that…

Photo

Utilizing findings from cancer research

Understanding immunity to SARS-CoV-2

Why does every person react differently to an infection with the coronavirus SARS-CoV-2? Why do some people have no symptoms or only mild symptoms of COVID-19, the disease which it causes? And why do…

Photo

Reprogramming viruses

From cancer to corona: UK scientists switch research focus

A team of Cardiff University scientists has switched from researching cancer to work that could help towards a vaccine for coronavirus. The team at the School of Medicine usually work on…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH